Suboxone Tooth Decay Lawsuit Information
This article provides information on Suboxone lawsuits related to tooth decay. There have been legal actions brought against the manufacturers due to alleged severe tooth decay and other dental injuries caused by the drug, with claims that the risks were not adequately communicated to users prior to 2022.
Reportedly, Suboxone users before 2022 experienced unexpected dental issues, leading to these lawsuits. The dental problems associated with Suboxone may include tooth decay, loss, extractions, infections, cracked teeth, cavities, root canals, dental caries, and the need for crowns or replacements.
It is believed that those affected may be entitled to compensation. Legal experts suggest that the manufacturers might have to provide settlements to individuals who suffered severe dental injuries due to the use of Suboxone.
As of 2024, investigations are ongoing into claims against the drug’s manufacturers regarding their alleged failure to adequately warn about the risks of severe tooth decay and other dental problems linked to Suboxone.
For those who believe they might be affected, it is advised to seek a case review from a legal professional. Various law firms are available to provide consultations on potential claims relating to Suboxone and its side effects.
Suboxone Lawsuit Updates
January 23, 2024
New Suboxone lawsuits are being initiated in several states across the United States in 2024. These states include Arkansas, California, Connecticut, District of Columbia, Florida, Maine, Maryland, Massachusetts, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and Wyoming.
January 16, 2024
A new lawsuit related to Suboxone was filed. The plaintiff, from Pennsylvania, alleges dental damage resulting from the use of Suboxone film. In 2013, Suboxone film was prescribed for opioid use disorder treatment, but the plaintiff claims they were not informed about the significant risk of dental erosion and decay associated with its use.
January 11, 2024
There have been no new Suboxone lawsuits filed recently, but more are expected before an upcoming MDL (Multi-District Litigation) hearing to demonstrate the volume of cases, potentially supporting a class action lawsuit.
January 4, 2023
There are concerns that the medication guide for Suboxone film does not adequately warn about the risk of tooth decay, although this information is included in the prescribing information. This omission has been a point of contention in ongoing legal discussions.
January 2, 2023
Ahead of a hearing on forming a Suboxone class action MDL, there are at least 15 pending cases in various federal districts. This number is expected to grow, with many more cases being investigated.
December 13, 2023
The defendants in the Suboxone lawsuits have responded to the request for class action MDL consolidation. They agree with the motion and suggest assigning the MDL to Judge Philip Calabrese in the Northern District of Ohio.
December 7, 2023
Recent developments in the efforts to establish a Suboxone class action lawsuit and the potential formation of an MDL are being closely followed. Legal experts suggest that a strong case exists for most victims pursuing a lawsuit.
November 27, 2023
Legal representatives for plaintiffs have requested the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federal lawsuits related to Suboxone into a single multidistrict litigation (MDL). This move aims to streamline the pretrial process and potentially expedite settlements. These lawsuits are currently spread across various federal districts, and consolidation into an MDL would provide a more efficient way to handle these cases, which share similar allegations.
November 3, 2023
In a recent surge of legal activity, fourteen new Suboxone product liability lawsuits have been filed against the manufacturer, Indivior, in various federal courts. A significant number of these cases have been filed in the Northern District of Ohio, which currently has the highest concentration of Suboxone cases.
November 2, 2023
A lawsuit has been filed in Wood County, Ohio, by a man who suffered dental injuries allegedly due to the use of Suboxone film. Prescribed Suboxone for opioid addiction management, the plaintiff claims to have sustained permanent tooth damage, leading to substantial dental procedures and pain and suffering.
October 30, 2023
Indivior, the manufacturer of Suboxone, is facing multiple legal challenges. Alongside the growing number of lawsuits related to tooth decay caused by Suboxone, Indivior is also involved in defending against a lawsuit under the False Claims Act. This lawsuit accuses the company of participating in an illegal kickback scheme. A recent ruling by a federal judge has allowed this case to proceed, rejecting Indivior’s motion to dismiss.
October 24, 2023
Indivior, the manufacturer of Suboxone, has agreed to a $385 million settlement in an antitrust lawsuit. This lawsuit accused the company of impeding generic competition by introducing a dissolving film tab version of Suboxone as the patent on the original pill version was nearing expiration. This settlement follows a previous $900 million payment by Indivior to settle a similar case brought by state and federal governments.
October 16, 2023
A recent federal court filing in Geauga County, Ohio, marks another Suboxone tooth decay lawsuit (King v. Indivior, Inc, et al. 1:23-cv-01924, N.D. Ohio). The plaintiff, who developed an addiction to opioids following a prescription, was later prescribed Suboxone for addiction treatment. After 16 months on Suboxone, the plaintiff suffered severe tooth decay, leading to the extraction of several teeth. The lawsuit alleges a lack of awareness about Suboxone’s potential for causing tooth decay on the part of both the plaintiff and his doctor.
Suboxone is a medication primarily used in treating opioid addiction. It combines buprenorphine, a partial opioid agonist, and naloxone, an opioid antagonist. Buprenorphine helps reduce withdrawal symptoms and cravings by activating opioid receptors in the brain to a lesser degree than full agonists, while naloxone reverses opioid effects and can trigger withdrawal symptoms if misused. Suboxone is available in sublingual film or tablet form and is usually part of a comprehensive treatment program that includes counseling and therapy.
While Suboxone has been effective in aiding individuals in managing opioid addiction and transitioning towards a drug-free life, it is not without potential risks and side effects. Commonly reported side effects of Suboxone include nausea, headache, sweating, constipation, and sleep disturbances.
These side effects are generally considered manageable and are often perceived as less significant compared to the benefits of reducing opioid dependence. The awareness of these risks is typically attributed to the information provided by the manufacturers and distributors of the drug. This allows both doctors and patients to make informed decisions regarding its use, weighing the known risks against the potential benefits.
Suboxone Lawsuits Overview
There is a growing number of lawsuits related to Suboxone, specifically focusing on tooth decay and dental injuries. These lawsuits allege that the drug’s manufacturers were aware of the severe dental side effects caused by Suboxone but failed to provide adequate warnings until 2022. Many of the claims involve patients who used Suboxone before 2022 and subsequently experienced tooth decay, broken teeth, and other dental injuries.
Individuals who have suffered severe dental injuries potentially linked to Suboxone use may be exploring legal avenues for compensation. Legal experts suggest that these cases could result in reasonable settlement amounts from the defendants to the affected patients.
There is an ongoing investigation into claims against Suboxone’s manufacturers, focusing on their alleged failure to adequately warn about the risks of severe tooth decay and other dental issues. Legal actions regarding this matter began in 2023 and are expected to continue into 2024.
The nature of legal representation in such cases often involves no upfront fees or expenses, with costs incurred only upon the successful resolution of a claim, typically in the form of a settlement amount or jury payout.
The Risk of Dental Injuries from Suboxone
Studies have suggested that Suboxone sublingual films, which dissolve under the tongue, may contribute to tooth decay and other dental problems due to their acidic nature. Prolonged exposure to this acidity can damage tooth enamel, potentially leading to cavities, gum disease, and tooth loss. These issues can be painful and often require dental interventions like fillings, extractions, or implants.
Patients who began taking Suboxone in 2023 are likely aware of these risks, having discussed them with healthcare providers or read the information in the package insert. To mitigate these risks, patients are advised to practice diligent oral hygiene, including regular brushing and flossing, and to use fluoride toothpaste and mouthwash to fortify tooth enamel. Dietary changes, such as reducing sugar intake and consuming foods rich in calcium and vitamin D, can also promote dental health.
However, for those who used Suboxone before the inclusion of the 2022 warning, this risk might not have been known. Individuals who experienced significant dental issues without prior knowledge of these risks might explore legal options.
The Core Issue in Suboxone Lawsuits: Failure to Warn
For current users of Suboxone, awareness of dental risks is more likely due to information from healthcare professionals or package inserts. These users have the opportunity to take extra care of their oral health through vigilant hygiene practices, including regular brushing and flossing. Strengthening tooth enamel with fluoride-based products and adjusting dietary habits to reduce sugar intake and increase calcium and vitamin D can also be beneficial.
Additionally, patients have the option to consider alternative treatments for opioid withdrawal, weighing the risks and benefits of different medications.
No Warning Before 2022
Individuals who used Suboxone prior to 2022 were likely unaware of its potential dental risks. It wasn’t until June 2022 that the prescribing information for Suboxone film was updated to include warnings about dental issues. Those who suffered severe tooth decay or other dental injuries without prior knowledge of these risks might consider exploring legal options.
The Suboxone Study That Highlighted Dental Risks
A significant study in 2022 provided evidence supporting concerns about Suboxone’s link to dental injuries. The study compared three groups using different medications: sublingual buprenorphine/naloxone, transdermal buprenorphine, and oral naltrexone. It found that users of sublingual buprenorphine/naloxone experienced a higher incidence of dental problems, including cavities and tooth loss, compared to the other two groups.
The risk of dental problems for users of sublingual buprenorphine/naloxone was found to be 1.42 times higher than those using transdermal buprenorphine and 1.67 times higher than those using oral naltrexone. The study also noted significantly higher rates of dental caries or tooth loss in the sublingual buprenorphine/naloxone group.
Researchers suggest that the acidic nature of sublingual buprenorphine/naloxone could be a contributing factor. This medication, held under the tongue to dissolve, may expose teeth to acid for extended periods, potentially weakening tooth enamel and increasing vulnerability to decay.
Who Qualifies for a Suboxone Lawsuit in 2024?
Individuals who have used Suboxone sublingual films and subsequently developed severe dental issues such as tooth decay, tooth loss, extractions, broken teeth, or jaw bone injuries, may be potential plaintiffs in a Suboxone lawsuit. It is anticipated that if a Suboxone class action lawsuit leads to a settlement, higher compensation might be allocated to those requiring extensive dental treatments like implants or oral surgeries.
Primary Defendants in Suboxone Lawsuits
Indivior, Inc. and Aquestive Therapeutics Inc., the developers of Suboxone, are primary defendants in these lawsuits. Indivior, as the primary manufacturer, and Aquestive Therapeutics, a specialty pharmaceutical company, have a specific focus on buprenorphine-based drugs for opioid dependency treatment. Notably, Indivior was previously a division of Reckitt Benckiser (Reckitt), which still holds a significant share in Indivior and is often named in these lawsuits.
Indivior has faced legal challenges in the past, including a settlement with the Department of Justice for an alleged scheme related to the prescription of its drugs. This background may be a factor in the ongoing Suboxone lawsuits.
Estimated Settlement and Trial Values in Suboxone Lawsuits
The settlement value for successful Suboxone lawsuits involving tooth decay is estimated to range between $55,000 to $200,000. However, the potential jury payout for a trial could be significantly higher, potentially reaching millions of dollars. Factors such as the possibility of punitive damages and the specifics of each case could influence these amounts.
While these estimates are speculative and depend on the progress and outcomes of ongoing legal proceedings, they reflect the potential financial implications of the Suboxone lawsuits. The exact values will become clearer as the cases progress through the discovery phase and other legal developments.
Punitive Damages in Suboxone Litigation
Punitive damages may significantly influence the outcome of Suboxone litigation. Allegations suggest that the defendants knowingly disregarded the safety of consumers by providing false or misleading information about Suboxone’s safety and effectiveness, and failed to adequately instruct on or train for its use. They are accused of underrepresenting the risks, especially regarding dental erosion and decay, despite allegedly being aware of these issues.
Plaintiffs in jurisdictions where permissible are seeking punitive damages, arguing that the defendants’ actions were willful and recklessly disregarded consumer rights and safety. Such claims aim to both punish the defendants and deter future similar conduct, potentially leading to substantial jury awards if the evidence supports these allegations.
Suboxone Settlement History
In recent years, Indivior and other involved pharmaceutical companies have agreed to pay over $1 billion in settlements related to Suboxone. These settlements were primarily to resolve antitrust claims related to market practices and pricing strategies. However, settlements specifically addressing Suboxone-related tooth decay issues have not yet commenced.
Suboxone Class Action Lawsuit Status
A class action lawsuit (MDL) concerning Suboxone tooth decay is currently pending and is expected to be certified in February 2024. Given the extensive use of opioids and Suboxone in recent decades, the potential plaintiff field for this litigation is considerable. The high incidence of tooth decay among Suboxone users underscores the potential for a substantial class action lawsuit.
Joining the Suboxone Tooth Decay Lawsuit
Individuals affected by Suboxone-related dental issues are encouraged to seek legal consultation. Legal experts across the country are currently reviewing Suboxone cases. Those interested in exploring their legal options can contact legal professionals for more information and to determine their eligibility for participation in the lawsuit.